• Adam J Saltzman, Gregg W Stone, Bimmer E Claessen, Amar Narula, Selene Leon-Reyes, Giora Weisz, Bruce Brodie, Bernhard Witzenbichler, Giulio Guagliumi, Ran Kornowski, Dariusz Dudek, D Christopher Metzger, Alexandra J Lansky, Eugenia Nikolsky, George D Dangas, and Roxana Mehran.
• Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA.
• JACC Cardiovasc Interv. 2011 Sep 1;4(9):1011-9.

ObjectivesThis study sought to investigate the impact of chronic kidney disease (CKD) in patients undergoing percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) with different antithrombotic strategies.BackgroundCKD is associated with increased risk of adverse ischemic and hemorrhagic events after primary PCI for STEMI.MethodsHORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial was a multicenter, international, randomized trial comparing bivalirudin monotherapy or heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) during primary PCI in STEMI. CKD, defined as creatinine clearance <60 ml/min, was present at baseline in 554 of 3,397 patients (16.3%). Patients were followed for 3 years. Net adverse cardiac event (NACE) was defined as the composite of death, reinfarction, ischemia-driven target vessel revascularization (TVR), stroke or non-coronary artery bypass grafting (CABG)-related major bleeding.ResultsPatients with CKD compared with patients without had higher rates of NACE (41.4% vs. 23.8%, p < 0.0001), death (18.7% vs. 4.4%, p < 0.0001), and major bleeding (19.3% vs. 6.7%, p < 0.0001). Multivariable analysis identified baseline creatinine as an independent predictor of death at 3 years (hazard ratio: 1.51, 95% confidence interval: 1.21 to 1.87, p < 0.001). Patients with CKD randomized to bivalirudin monotherapy versus heparin plus GPI had no significant difference in major bleeding (19.0% vs. 19.6%, p = 0.72) or death (19.0% vs. 18.4%, p = 0.88) at 3 years. In patients with CKD, there was no difference in the rates of TVR in bare-metal stents (BMS) versus drug-eluting stents (DES) at 3 years (14.1% vs. 15.1%, p = 0.8).ConclusionsSTEMI patients with CKD have significantly higher rates of death and major bleeding compared with those without CKD. In patients with CKD, there appears to be no benefit of bivalirudin compared with heparin + GPI, or DES versus BMS during primary PCI in improving clinical outcomes.Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

54 keywords...

hide…